Healios KK (JP:4593) has released an update.
Claim 30% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Healios KK has made progress in its application for conditional approval of its MultiStem product for treating Acute Respiratory Distress Syndrome (ARDS) in Japan. Following positive results in Phase 2 studies, the company has reached an agreement with regulatory authorities on manufacturing details and is preparing for commercial production. Plans are underway for further consultation on the clinical aspects of the application in January.
For further insights into JP:4593 stock, check out TipRanks’ Stock Analysis page.